Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2024-02-08
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax and acalabrutinib work in treating patients
with mantle cell lymphoma that did not respond to previous treatment or has come back.
Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to
stay alive. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving venetoclax and acalabrutinib together may kill more cancer
cells in patients with mantle cell lymphoma.